The USPTO Patent Trial and Appeals Board (PTAB) upheld five Mallinckrodt $MNK patents of INOMAX (nitric oxide) gas for inhalation. The patents, which are valid till 2013, got challenged by Praxir Distribution. INOMAK has FDA�s approval. It improves oxygenation and lowers the need for extracorporeal membrane oxygenation in term and near-term (at least 34 weeks gestation) neonates with hypoxic respiratory failure linked with pulmonary hypertension in conjunction with ventilator support and other agents.